ENARADA, Bangalore, August 21, 2013:
Bangalore-based MetricStream, a market leader in Enterprise-wide Governance, Risk, Compliance (GRC) and Quality Management Solutions for global corporations, announced that it has been chosen by US based Onyx Pharmaceuticals, Inc., a global biopharmaceutical company, for its comprehensive quality management solution to manage a wide range of quality and compliance requirements, including quality audits, corrective action/preventive action (CAPA), product complaints, deviations, and change control.
The MetricStream solution will enable quality processes to be managed and tracked more effectively and efficiently, while simultaneously rolling up quality data from across the enterprise to be viewed at the top in real time. Using this data, stakeholders will be able to proactively mitigate quality risks, ensure compliance with quality standards, analyze trends, and make more informed decisions.
“We are delighted to help Onyx Pharmaceuticals enhance their quality management program through our leading-edge solution,” said Gaurav Kapoor, Chief Operating Officer at MetricStream. “Reputed organizations across Life Sciences, Pharmaceuticals, Medical Devices, and Healthcare choose to partner with us because we continue to push the envelope of innovation, and develop holistic and flexible solutions which enable organizations to successfully meet their quality, risk, and compliance objectives.”
“Patient Safety is important at Onyx Pharmaceuticals, and we employ some of the most sophisticated and cutting-edge technologies to monitor the safety and efficacy of our products,” said Ron Marchesani, Onyx’s Vice President, Quality. “With MetricStream’s help, we look forward to raising the bar even higher by implementing next-generation technology that will provide real-time quality data at our fingertips and strengthen decision-making.”
Headquartered in South San Francisco, California, Onyx Pharmaceuticals is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. In 2012, Onyx was recognized among the top 20 of the MedAdNews 21st Annual Top 100 Biotechnology Companies List.
